BIOMAT Database Logo BIOMAT Database Logo

A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. 1991

W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Hematology and Oncology Associates of Northeastern Pennsylvania Professional Corporation, Scranton, PA.

A combination of cisplatin administered as a 24-hour infusion and fluorouracil administered as a 5-day infusion was used to treat 97 patients with non-small-cell lung (NSCLC) cancer in a phase II trial. Thirty patients had stage IIIB disease; 67 patients, stage IV disease (new international classification). Patients with stage IIIB disease also received thoracic radiation after chemotherapy. The regimen was well tolerated, with 24% or less grade 3 or greater toxicities of all types. One toxic death was attributed to fluid overload. The response rate, partial and complete, was 43% (95% confidence interval, 27% to 63%), and median survival was 13.8 months for patients with stage IIIB disease. Response rates refer to the chemotherapy response. For patients with stage IV disease, the response rate was 34% (95% confidence interval, 24% to 47%), and median survival was 6.2 months. On this regimen, stable-disease patients with stage IV disease had survivals at least equal to responders.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
A study of oral etoposide, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small-cell lung cancer. A Mid-Atlantic Oncology Program study.
February 1992, American journal of clinical oncology,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. A MAOP study.
October 1991, American journal of clinical oncology,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
October 1997, Annals of oncology : official journal of the European Society for Medical Oncology,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
January 1997, Cancer chemotherapy and pharmacology,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
January 2001, Acta oncologica (Stockholm, Sweden),
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
October 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Crizotinib: in locally advanced or metastatic non-small cell lung cancer.
January 2012, Drugs,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer.
September 1997, Changgeng yi xue za zhi,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
August 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
W Heim, and G L Wampler, and J J Lokich, and H D Brereton, and S J Scialla, and F LaLuna, and J D Ahlgren, and J Nevin, and J G Fryer, and D Alt
A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
May 2005, Chemotherapy,
Copied contents to your clipboard!